XtalPi Partners with Parthenon Therapeutics to Harness AI for Solid Tumor Antibody Development
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...
United Laboratories’ UBT251 Receives Tacit Approval for Obesity Clinical Study in China
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1...
Zai Lab’s Margenza (Margetuximab) Approved by China’s NMPA for HER2-Positive Breast Cancer
The National Medical Products Administration (NMPA) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB,...
MicuRx Pharmaceuticals Initiates Phase III Trial for MRX-4 in Complex Skin Infections
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...
EOC Pharma Group and Nanopeptide Biotechnology Forge Partnership for siRNA Drug Development
China-based EOC Pharma Group has announced a strategic partnership with fellow country siRNA firm, Nanopeptide...
Rapid Medical’s Tigertriever Receives Chinese Approval as Adjustable Thrombectomy Device
Israel-based medical device company Rapid Medical has announced that its revascularization device, Tigertriever, has received...
Genexine’s Eftansomatropin Alfa Achieves Phase III Endpoints in Growth Hormone Deficiency Trial
South Korea-based Genexine (KOSDAQ: 095700) has announced that its long-acting growth hormone product candidate, eftansomatropin...
Huadong Medicine Secures Exclusive Rights to MC2 Therapeutics’ Plaque Psoriasis Therapy in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2...
Innovac Therapeutics Secures $18 Million in Pre-Series A Financing for mRNA Vaccine Development
Innovac Therapeutics, a Massachusetts-based mRNA vaccine developer, has announced the successful completion of its Pre-Series...
AstraZeneca’s Soliris Gains Approval for Pediatric Generalized Myasthenia Gravis in Japan
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received an...
AstraZeneca and Daiichi Sankyo’s Enhertu Earns Two BTDs for HER2+ Malignancies
The US Food and Drug Administration (FDA) has granted AstraZeneca (AZ; NASDAQ: AZN) and Daiichi...
Bayer Funds Landmark Trials for Kerendia in Heart Failure Treatment Expansion
Germany-based pharmaceutical company Bayer (ETR: BAYN) has announced funding for three investigator-sponsored collaborative studies aimed...
EMA and FDA Review AbbVie’s Skyrizi for Ulcerative Colitis Indication Extension
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted...
Shandong Buchang Pharmaceuticals’ BC001 for mCRC Accepted for Review by NMPA
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced that the...
Sirnaomics’ STP707 siRNA Drug Shows Promising Results in Phase I Solid Tumor Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has revealed that all patients have been...
Servier Group’s Pancreatic Cancer Therapy Onivyde Launches in Major Chinese Cities
France-based Servier has announced the first prescriptions for its pancreatic cancer therapy, Onivyde (irinotecan), in...
Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus
China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first...
CDE Releases 73rd Batch of Chemical Generic Reference Preparations with Updates
The Center for Drug Evaluation (CDE) has released the 73rd batch of chemical generic reference...
Lee’s Pharmaceutical Holdings Ltd Reports H1 2023 Revenue Dip Amid Product Portfolio Growth
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its financial report for the first...
Watchmaker Genomics and Exact Sciences Corporation Ink Deal to Advance TAPS Technology
US-based Watchmaker Genomics has announced a multi-year, co-exclusive agreement with compatriot firm Exact Sciences Corporation...